PMID: 22570063May 10, 2012Paper

Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies

Brain and nerve = Shinkei kenkyū no shinpo
Mikio Shoji

Abstract

Recent advances in biomarker studies compiled from the Alzheimer's Disease Neuroimaging Initiative (ADNI) are summarized here. CSF Aβ42, total tau, and phosphorylated tau181 are the most sensitive biomarkers for diagnosing Alzheimer's disease (AD) and predicting the onset of AD in cases with mild cognitive impairment (MCI) due to AD. Many perspective studies on PiB-PET, FDG-PET, MRI volumetry, and some neuropsychiatric tests have provided evidence for the usefulness of these biomarkers for diagnosing AD and MCI due to AD. Basic and clinical studies have contributed considerably to the establishment of clinical evidence that supports the usefulness of these markers. Given the progress in the diagnosis of preclinical AD, discovery of therapy that is essential for the cure of AD is expected soon.

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Related Papers

International Journal of Alzheimer's Disease
Mikio Shoji
Psychological Medicine
I H G B RamakersAlzheimer's Disease Neuroimaging Initiative and DESCRIPA Investigators
Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Jesus J GomarAlzheimer's Disease Neuroimaging Initiative
© 2021 Meta ULC. All rights reserved